--- title: A Simple Guide to 510(k) Applications for Medical Devices description: Easy Guidance for Abbreviated, Special, and Traditional 510(k) Clearance Applications. image: https://blog.scalehealth.com/hubfs/Hero2-1.jpg --- [![Sierra Labs](https://blog.scalehealth.com/hubfs/Sierralabs_January2019%20Theme/Images/sierra-labs-logo.png)](https://www.sierralabs.com/) - Products - [Sierra Policies & Procedures](https://www.sierralabs.com/policies-procedures) - [Sierra Document Automation](https://www.sierralabs.com/document-automation) - [Sierra Quality Management](https://www.sierralabs.com/quality-management) - [Sierra GxP Cloud Validation](https://www.sierralabs.com/cloud-validation) - [Services](https://www.sierralabs.com/services) - [About Us](https://www.sierralabs.com/about) - [Partner](https://campaign.sierralabs.com/partner-with-sierra-labs) - [Blog](https://blog.scalehealth.com) - [Contact Us](https://www.sierralabs.com/document-automation/#contact-us) [Contact Us](https://www.sierralabs.com/document-automation/#contact-us)   ## Sierra Labs Blog This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. # A Simple Guide to 510(k) Applications for Medical Devices Posted by [Sierra Labs](https://blog.scalehealth.com/author/sierra-labs) on Aug 1, 2023, 10:42:00 AM - [Tweet](https://twitter.com/share) Easy Guidance for Abbreviated, Special, and Traditional 510(k) Clearance Applications ![Hero2-1](https://blog.scalehealth.com/hs-fs/hubfs/Hero2-1.jpg?width=883&name=Hero2-1.jpg)   With medical device technologies evolving at an unprecedented rate, the FDA has experienced an overload of 510(k) submissions. In September 2019, the FDA revised its guidance documents for this submission in order to make it more streamlined and keep up with market demands. The Premarket 510(k) submission is the main pathway for medical devices to receive market approval here in the US. With constant updates on existing regulations, it can get confusing to figure out the best regulatory method for your device. The following guide will clarify the types of 510(k) submissions there are giving your team a great starting point for regulatory submission. **What is Substantial Equivalence?** "Substantial Equivalence" is the method used by the FDA to prove to them that your new device is at least as safe and effective as the predicate device. A device is substantially equivalent if, in comparison to a predicate, it: - has the same intended use as the predicate - has the same technological characteristics as the predicate - has different technological characteristics and the information submitted to FDA - does not raise new questions about safety and effectiveness This does not mean that the devices must be identical, as there are a number of factors that go come into play when establishing equivalence such as design, materials, manufacturing process, performance, safety, effectiveness, labeling, etc. **Premarket Notification 510(k) Pathways** Using the guidance documents, we have outlined the FDA's three established timelines for reviewing a 510(k) submission: Traditional 510(k): - Used by most companies introducing a new Class II device and must submit a Traditional 510k Premarket Notification (21-section document).   - FDA’s clearance of a Traditional 510k is 90 days. Special 510(k): - Used when there is a design change or a modification to a device you have previously cleared that does not affect the intended use.   - FDA’s clearance of a Special 510k is 30 days. Abbreviated 510(k): - Used when there is guidance documents from the FDA and a special control has been established by the FDA for this device and consensus standards.   - FDA's clearance of Abbreviated 510(k) is 90 days. ![typesof510k](https://blog.scalehealth.com/hs-fs/hubfs/typesof510k.jpg?width=600&name=typesof510k.jpg) **Traditional 510(k) Program** Is the basic pathway for any medical device regardless of its class type. The 510(k) premarket notification program is primarily intended for medical devices that are “substantially equivalent” (using 21 CFR 807) to other medical devices that have previously received market clearance from the FDA. Manufacturers may use the traditional format when: - PMA Not Required - Exclusion from this type of submission applies to those devices for which Premarket Approval Application (PMA) is required. - Established SE - Provide sufficient information to allow FDA reviewers to determine whether the subject medical device is substantially equivalent to an identified predicate device. **Abbreviated 510(k) Program** Used by the FDA as an optional approach to the Traditional 510(k) Program to demonstrate SE in premarket notifications. Device manufacturers can choose the Abbreviated 510(k) pathway to demonstrate SE in premarket notifications by using one or more of the following: - FDA Guidance Document - Specifying device description, device design, risk management, and test methods used to address performance characteristics will help verify SE. Reports should also include information regarding any deviations or alternative methods used to demonstrate substantial equivalence that are not described in the guidance. - Special Controls   - Specifying how this special control has been used to address a special risk or issue will help demonstrate SE. Special controls are defined in section 513(a)(1)(B) of the FD&C Act as those controls, such as performance standards, post-marketing surveillance, patient registries, development and dissemination of guidelines, recommendations, and other appropriate actions that provide reasonable assurance of device’s safety and effectiveness. - Voluntary Consensus Standard(s) - Specifying the basis of use with supportive information and data must match the manufacturer's voluntary consensus standard that is recognized by the FDA. **Special 510(k) Program** The Special 510(k) pathway was previously limited to the review of changes to a cleared device that did not impact its intended use or alter the device’s fundamental scientific technology. In the 2019 published version of the guidance, the FDA has revamped its approach to make this pathway more inclusive by allowing for specific intended use changes and technological changes to be reviewed under a Special 510(k). Manufacturers can submit their device modifications as a Special 510(k) if they meet the following minimum requirements: - Previously Authorized and Marketed Device - The proposed change is submitted by the manufacturer legally authorized to market the existing device, meaning the modification must be made to the manufacturer’s own device. - Unnecessary Performance Data - Performance data is unnecessary or may be evaluated using well-established methods which are available by the FDA to evaluate the change. - Risk Analysis Format - All performance data necessary to support substantial equivalence (SE) can be reviewed in a summary or risk analysis format. **Convert A Special 510(k) to a Traditional 510(k)** FDA can convert the Special 510(k) to a Traditional 510(k) if SE determination cannot be made through information submitted in a Special 510(k). If there is an issue, the FDA will include this in the [Refuse To Accept (RTA) letter.](https://blog.scalehealth.com/6-preliminary-questions-around-fda-rta-policy-for-510k) This type of conversion results in delays as the content of the Traditional 510(k) varies from a Special 510(k) and this data gap needs to be fixed for a complete review. Therefore, in cases where the manufacturer is unsure about use of Special 510(k) pathway, a Pre-Submission meeting with FDA can be explored further to achieve regulatory success. **Defining a Regulatory Strategy** Since every submission is unique in the eyes of the FDA, some manufacturers might have a tougher time finding "substantial equivalence" or a predicate for their device. This will in turn cause a delay in submission. Along with guidance updates, the FDA has become more flexible in engaging with newer medical device companies to answer any questions or concerns that may arise. This engagement process is all part of your regulatory strategy, which is something we advise you to have even before submitting any documents! If you need some further insight to how a regulatory strategy works, be sure to check out our [8 Guidelines for Your Medical Device Regulatory Strategy.](https://blog.scalehealth.com/8-guidelines-for-your-medical-device-regulatory-strategy) **Benefits of** **Utilizing**** Pre-Submissions** Even with an action plan, it can be easy to miss important steps throughout the process of your regulatory submission and we want to assure you avoid any delays in time and organization. Pre-Submissions can be a beneficial way to effectively prepare for your 510(k) submission to FDA. [FDA Pre-Submission program](https://blog.scalehealth.com/a-quick-easy-guide-to-fda-pre-submissions) is a meeting with the FDA where they provide you with feedback before submitting your formal medical device application. It is voluntary, not mandatory, and is a way for you to fix gaps in your application before submitting your final version. A sort of practice exam if you will, with detailed feedback on ways to improve for the real deal.  We have helped various medical device companies like yours prepare for 510(k) submissions in each of the varying timelines. We have also led them through Pre-Submission programs, assuring they are comfortable and confident in their FDA interactions. We know speaking with the FDA can be a daunting first step toward achieving market approval. For your convenience, we have created a free questionnaire to help you prepare for any questions the FDA may have. Try it below to help you get ready for your meeting with the FDA! **Want to see how Sierra QMS can help your organization? Click Here for a Free Trial!** [![Get my Free Trial](https://hubspot-no-cache-na2-prod.s3.amazonaws.com/cta/default/5229980/781c7d54-0e75-43d8-9494-ffda81c600d1.png)](https://hubspot-cta-redirect-na2-prod.s3.amazonaws.com/cta/redirect/5229980/781c7d54-0e75-43d8-9494-ffda81c600d1) Quick and easy! Topics: [FDA](https://blog.scalehealth.com/tag/fda), [Medical Device](https://blog.scalehealth.com/tag/medical-device), [FDA Approval](https://blog.scalehealth.com/tag/fda-approval), [Medical Device Company](https://blog.scalehealth.com/tag/medical-device-company), [FDA Pre-Sub](https://blog.scalehealth.com/tag/fda-pre-sub), [FDA Regulation](https://blog.scalehealth.com/tag/fda-regulation), [Regulatory Pathway](https://blog.scalehealth.com/tag/regulatory-pathway), [Regulatory Strategy](https://blog.scalehealth.com/tag/regulatory-strategy), [Quality System Regulation](https://blog.scalehealth.com/tag/quality-system-regulation), [rta](https://blog.scalehealth.com/tag/rta), [510(k)](https://blog.scalehealth.com/tag/510k), [21 cfr 807](https://blog.scalehealth.com/tag/21-cfr-807), [special 510(k)](https://blog.scalehealth.com/tag/special-510k), [abbreviated 510(k)](https://blog.scalehealth.com/tag/abbreviated-510k), [traditional 510(k)](https://blog.scalehealth.com/tag/traditional-510k) ## Featured posts ### Topics - [FDA (42)](https://blog.scalehealth.com/tag/fda) - [QMS (31)](https://blog.scalehealth.com/tag/qms) - [Compliance (28)](https://blog.scalehealth.com/tag/compliance) - [Medical Device (27)](https://blog.scalehealth.com/tag/medical-device) - [Medical Device Company (26)](https://blog.scalehealth.com/tag/medical-device-company) - [SaMD (26)](https://blog.scalehealth.com/tag/samd) - [Data Security (17)](https://blog.scalehealth.com/tag/data-security) - [Regulations (17)](https://blog.scalehealth.com/tag/regulations) - [21 CFR Part 820 (15)](https://blog.scalehealth.com/tag/21-cfr-part-820) - [Medical Devices (15)](https://blog.scalehealth.com/tag/medical-devices) - [ISO (14)](https://blog.scalehealth.com/tag/iso) - [FDA Approval (13)](https://blog.scalehealth.com/tag/fda-approval) - [Agile (12)](https://blog.scalehealth.com/tag/agile) - [Data Privacy (12)](https://blog.scalehealth.com/tag/data-privacy) - [FDA Regulation (12)](https://blog.scalehealth.com/tag/fda-regulation) - [ISO 13485 (11)](https://blog.scalehealth.com/tag/iso-13485) - [SaMD Development (11)](https://blog.scalehealth.com/tag/samd-development) - [CFR Part 820 (10)](https://blog.scalehealth.com/tag/cfr-part-820) - [Data Requirements (10)](https://blog.scalehealth.com/tag/data-requirements) - [Document Controls (10)](https://blog.scalehealth.com/tag/document-controls) - [FDA Pre-Sub (10)](https://blog.scalehealth.com/tag/fda-pre-sub) - [Health Technology (10)](https://blog.scalehealth.com/tag/health-technology) - [Regulatory Pathway (10)](https://blog.scalehealth.com/tag/regulatory-pathway) - [AI (9)](https://blog.scalehealth.com/tag/ai) - [Documentation (9)](https://blog.scalehealth.com/tag/documentation) - [GxP Cloud (9)](https://blog.scalehealth.com/tag/gxp-cloud) - [Quality System Regulation (9)](https://blog.scalehealth.com/tag/quality-system-regulation) - [Technology (9)](https://blog.scalehealth.com/tag/technology) - [Validated Cloud (9)](https://blog.scalehealth.com/tag/validated-cloud) - [risk (9)](https://blog.scalehealth.com/tag/risk) - [Cloud (8)](https://blog.scalehealth.com/tag/cloud) - [FDA Audit (8)](https://blog.scalehealth.com/tag/fda-audit) - [GxP (8)](https://blog.scalehealth.com/tag/gxp) - [Health Data (8)](https://blog.scalehealth.com/tag/health-data) - [ISO 13485:2016 (8)](https://blog.scalehealth.com/tag/iso-134852016) - [ISO 14971 (8)](https://blog.scalehealth.com/tag/iso-14971) - [Manufacturing (8)](https://blog.scalehealth.com/tag/manufacturing) - [PHI (8)](https://blog.scalehealth.com/tag/phi) - [Personal Health Information (8)](https://blog.scalehealth.com/tag/personal-health-information) - [Conformity (7)](https://blog.scalehealth.com/tag/conformity) - [Healthcare (7)](https://blog.scalehealth.com/tag/healthcare) - [Life Science QMS (7)](https://blog.scalehealth.com/tag/life-science-qms) - [Medical Solutions (7)](https://blog.scalehealth.com/tag/medical-solutions) - [Product Development (7)](https://blog.scalehealth.com/tag/product-development) - [Regulatory Strategy (7)](https://blog.scalehealth.com/tag/regulatory-strategy) - [SaMD QMS (7)](https://blog.scalehealth.com/tag/samd-qms) - [Software Requirement Specification (7)](https://blog.scalehealth.com/tag/software-requirement-specification) - [Standards (7)](https://blog.scalehealth.com/tag/standards) - [21 CFR (6)](https://blog.scalehealth.com/tag/21-cfr) - [Quality Management System (6)](https://blog.scalehealth.com/tag/quality-management-system) - [Quality Processes (6)](https://blog.scalehealth.com/tag/quality-processes) - [Regulatory Roadmap (6)](https://blog.scalehealth.com/tag/regulatory-roadmap) - [eHealth (6)](https://blog.scalehealth.com/tag/ehealth) - [21 CFR Part 11 (5)](https://blog.scalehealth.com/tag/21-cfr-part-11) - [Artificial Intelligence (5)](https://blog.scalehealth.com/tag/artificial-intelligence) - [CAPA (5)](https://blog.scalehealth.com/tag/capa) - [COVID19 (5)](https://blog.scalehealth.com/tag/covid19) - [Design Controls (5)](https://blog.scalehealth.com/tag/design-controls) - [Digital Health (5)](https://blog.scalehealth.com/tag/digital-health) - [Health Tech (5)](https://blog.scalehealth.com/tag/health-tech) - [Jira Cloud (5)](https://blog.scalehealth.com/tag/jira-cloud) - [Jira QMS (5)](https://blog.scalehealth.com/tag/jira-qms) - [New Drugs (5)](https://blog.scalehealth.com/tag/new-drugs) - [QMS healthcare (5)](https://blog.scalehealth.com/tag/qms-healthcare) - [Sierra QMS (5)](https://blog.scalehealth.com/tag/sierra-qms) - [training management (5)](https://blog.scalehealth.com/tag/training-management) - [Automation (4)](https://blog.scalehealth.com/tag/automation) - [Biopharma (4)](https://blog.scalehealth.com/tag/biopharma) - [Business Associates (4)](https://blog.scalehealth.com/tag/business-associates) - [Communication (4)](https://blog.scalehealth.com/tag/communication) - [Covered Entities (4)](https://blog.scalehealth.com/tag/covered-entities) - [Data Integrity (4)](https://blog.scalehealth.com/tag/data-integrity) - [Development Change (4)](https://blog.scalehealth.com/tag/development-change) - [Drug Approval (4)](https://blog.scalehealth.com/tag/drug-approval) - [GAMP5 (4)](https://blog.scalehealth.com/tag/gamp5) - [HIPAA (4)](https://blog.scalehealth.com/tag/hipaa) - [HIPAA Compliance (4)](https://blog.scalehealth.com/tag/hipaa-compliance) - [Health Applications (4)](https://blog.scalehealth.com/tag/health-applications) - [Integrated QMS (4)](https://blog.scalehealth.com/tag/integrated-qms) - [Medical Device Startups (4)](https://blog.scalehealth.com/tag/medical-device-startups) - [Pre-Submission (4)](https://blog.scalehealth.com/tag/pre-submission) - [Product Lifecycle (4)](https://blog.scalehealth.com/tag/product-lifecycle) - [Quality Roadmap (4)](https://blog.scalehealth.com/tag/quality-roadmap) - [Recall (4)](https://blog.scalehealth.com/tag/recall) - [Regulatory Approach (4)](https://blog.scalehealth.com/tag/regulatory-approach) - [Remote Work (4)](https://blog.scalehealth.com/tag/remote-work) - [Scale-ups (4)](https://blog.scalehealth.com/tag/scale-ups) - [Software (4)](https://blog.scalehealth.com/tag/software) - [Streamline Workflows (4)](https://blog.scalehealth.com/tag/streamline-workflows) - [document management (4)](https://blog.scalehealth.com/tag/document-management) - [ePHI (4)](https://blog.scalehealth.com/tag/ephi) - [510(k) (3)](https://blog.scalehealth.com/tag/510k) - [COVID-19 Solution (3)](https://blog.scalehealth.com/tag/covid-19-solution) - [Case Study (3)](https://blog.scalehealth.com/tag/case-study) - [Compliance Process (3)](https://blog.scalehealth.com/tag/compliance-process) - [Cybersecurity (3)](https://blog.scalehealth.com/tag/cybersecurity) - [DTx (3)](https://blog.scalehealth.com/tag/dtx) - [Design Verification (3)](https://blog.scalehealth.com/tag/design-verification) - [Document Automation Tools (3)](https://blog.scalehealth.com/tag/document-automation-tools) - [FDA Standard (3)](https://blog.scalehealth.com/tag/fda-standard) - [GAMP (3)](https://blog.scalehealth.com/tag/gamp) - [HIPAA Checklist (3)](https://blog.scalehealth.com/tag/hipaa-checklist) - [Hardware-based (3)](https://blog.scalehealth.com/tag/hardware-based) - [IEC 62304 (3)](https://blog.scalehealth.com/tag/iec-62304) - [ISPE (3)](https://blog.scalehealth.com/tag/ispe) - [Iterative Process (3)](https://blog.scalehealth.com/tag/iterative-process) - [Life Science (3)](https://blog.scalehealth.com/tag/life-science) - [Medical Technology (3)](https://blog.scalehealth.com/tag/medical-technology) - [Pharma (3)](https://blog.scalehealth.com/tag/pharma) - [Predicate Device (3)](https://blog.scalehealth.com/tag/predicate-device) - [Product Requirements Document (3)](https://blog.scalehealth.com/tag/product-requirements-document) - [QMS for SaMD Startups (3)](https://blog.scalehealth.com/tag/qms-for-samd-startups) - [Risk Management (3)](https://blog.scalehealth.com/tag/risk-management) - [SOC (3)](https://blog.scalehealth.com/tag/soc) - [SOC 2 (3)](https://blog.scalehealth.com/tag/soc-2) - [SOP (3)](https://blog.scalehealth.com/tag/sop) - [SaMD Startups (3)](https://blog.scalehealth.com/tag/samd-startups) - [Software Development (3)](https://blog.scalehealth.com/tag/software-development) - [Telecare (3)](https://blog.scalehealth.com/tag/telecare) - [Telehealth (3)](https://blog.scalehealth.com/tag/telehealth) - [eQMS (3)](https://blog.scalehealth.com/tag/eqms) - [AWS (2)](https://blog.scalehealth.com/tag/aws) - [Audit Trails (2)](https://blog.scalehealth.com/tag/audit-trails) - [CDER (2)](https://blog.scalehealth.com/tag/cder) - [CE Marking (2)](https://blog.scalehealth.com/tag/ce-marking) - [CFR (2)](https://blog.scalehealth.com/tag/cfr) - [Center for Biologics Evaluation and Research (2)](https://blog.scalehealth.com/tag/center-for-biologics-evaluation-and-research) - [Center for Drug Evaluation and Research (2)](https://blog.scalehealth.com/tag/center-for-drug-evaluation-and-research) - [Clinical Evaluation (2)](https://blog.scalehealth.com/tag/clinical-evaluation) - [Corrective Action Preventive Action (2)](https://blog.scalehealth.com/tag/corrective-action-preventive-action) - [Document Automation (2)](https://blog.scalehealth.com/tag/document-automation) - [Document Control (2)](https://blog.scalehealth.com/tag/document-control) - [Documentation Automation (2)](https://blog.scalehealth.com/tag/documentation-automation) - [Electronic Records (2)](https://blog.scalehealth.com/tag/electronic-records) - [GMP (2)](https://blog.scalehealth.com/tag/gmp) - [General Controls (2)](https://blog.scalehealth.com/tag/general-controls) - [HITRUST (2)](https://blog.scalehealth.com/tag/hitrust) - [HITRUST CSF (2)](https://blog.scalehealth.com/tag/hitrust-csf) - [ML (2)](https://blog.scalehealth.com/tag/ml) - [Machine Learning (2)](https://blog.scalehealth.com/tag/machine-learning) - [New Draft (2)](https://blog.scalehealth.com/tag/new-draft) - [Pharmaceutical (2)](https://blog.scalehealth.com/tag/pharmaceutical) - [Pre-market approval (2)](https://blog.scalehealth.com/tag/pre-market-approval) - [QS (2)](https://blog.scalehealth.com/tag/qs) - [Risk Classification (2)](https://blog.scalehealth.com/tag/risk-classification) - [Risk Managment (2)](https://blog.scalehealth.com/tag/risk-managment) - [Sierra Policies (2)](https://blog.scalehealth.com/tag/sierra-policies) - [Sierra Services (2)](https://blog.scalehealth.com/tag/sierra-services) - [Standard Operating Procedure (2)](https://blog.scalehealth.com/tag/standard-operating-procedure) - [fda submission (2)](https://blog.scalehealth.com/tag/fda-submission) - [mHealth Wearables (2)](https://blog.scalehealth.com/tag/mhealth-wearables) - [rta (2)](https://blog.scalehealth.com/tag/rta) - [software as medical device (2)](https://blog.scalehealth.com/tag/software-as-medical-device) - [21 cfr 807 (1)](https://blog.scalehealth.com/tag/21-cfr-807) - [513G (1)](https://blog.scalehealth.com/tag/513g) - [AAMI TIR45 (1)](https://blog.scalehealth.com/tag/aami-tir45) - [AICPA (1)](https://blog.scalehealth.com/tag/aicpa) - [ANVISA (1)](https://blog.scalehealth.com/tag/anvisa) - [Agência Nacional de Vigilância Sanitária (1)](https://blog.scalehealth.com/tag/agência-nacional-de-vigilância-sanitária) - [Amazon Web Services (1)](https://blog.scalehealth.com/tag/amazon-web-services) - [Analytical Validation (1)](https://blog.scalehealth.com/tag/analytical-validation) - [Annex 11 (1)](https://blog.scalehealth.com/tag/annex-11) - [Australian Therapeutic Goods Administration (1)](https://blog.scalehealth.com/tag/australian-therapeutic-goods-administration) - [BLA (1)](https://blog.scalehealth.com/tag/bla) - [Backlog (1)](https://blog.scalehealth.com/tag/backlog) - [Biologic Approval (1)](https://blog.scalehealth.com/tag/biologic-approval) - [Business Goals (1)](https://blog.scalehealth.com/tag/business-goals) - [CGMP (1)](https://blog.scalehealth.com/tag/cgmp) - [Cannabis (1)](https://blog.scalehealth.com/tag/cannabis) - [Cannabis Compliance (1)](https://blog.scalehealth.com/tag/cannabis-compliance) - [Change Control (1)](https://blog.scalehealth.com/tag/change-control) - [Client Reference (1)](https://blog.scalehealth.com/tag/client-reference) - [Clinical Development (1)](https://blog.scalehealth.com/tag/clinical-development) - [Clinical Validation (1)](https://blog.scalehealth.com/tag/clinical-validation) - [Code Reviews (1)](https://blog.scalehealth.com/tag/code-reviews) - [Conference (1)](https://blog.scalehealth.com/tag/conference) - [Coronavirus (1)](https://blog.scalehealth.com/tag/coronavirus) - [Current Good Manufacturing Practice (1)](https://blog.scalehealth.com/tag/current-good-manufacturing-practice) - [Customer Complaint (1)](https://blog.scalehealth.com/tag/customer-complaint) - [Data Transfer (1)](https://blog.scalehealth.com/tag/data-transfer) - [Design Changes (1)](https://blog.scalehealth.com/tag/design-changes) - [Design History File (1)](https://blog.scalehealth.com/tag/design-history-file) - [Design Transfer (1)](https://blog.scalehealth.com/tag/design-transfer) - [Development Team (1)](https://blog.scalehealth.com/tag/development-team) - [Device Classification (1)](https://blog.scalehealth.com/tag/device-classification) - [Device Software Functions (1)](https://blog.scalehealth.com/tag/device-software-functions) - [Document Publishing (1)](https://blog.scalehealth.com/tag/document-publishing) - [Drug Manufacturing (1)](https://blog.scalehealth.com/tag/drug-manufacturing) - [EUA (1)](https://blog.scalehealth.com/tag/eua) - [Electronic Signatures (1)](https://blog.scalehealth.com/tag/electronic-signatures) - [Emergency Use Authorization (1)](https://blog.scalehealth.com/tag/emergency-use-authorization) - [Enforcement Discretion (1)](https://blog.scalehealth.com/tag/enforcement-discretion) - [Engineering (1)](https://blog.scalehealth.com/tag/engineering) - [Ethos Automated System (1)](https://blog.scalehealth.com/tag/ethos-automated-system) - [FDA Draft (1)](https://blog.scalehealth.com/tag/fda-draft) - [HHS (1)](https://blog.scalehealth.com/tag/hhs) - [Hand Sanitizer (1)](https://blog.scalehealth.com/tag/hand-sanitizer) - [Hardware Development (1)](https://blog.scalehealth.com/tag/hardware-development) - [IEC (1)](https://blog.scalehealth.com/tag/iec) - [IEC 60601 (1)](https://blog.scalehealth.com/tag/iec-60601) - [IEC 60601:1 (1)](https://blog.scalehealth.com/tag/iec-606011) - [IEC 62366  (1)](https://blog.scalehealth.com/tag/iec-62366) - [IFU (1)](https://blog.scalehealth.com/tag/ifu) - [IND (1)](https://blog.scalehealth.com/tag/ind) - [ISO 13485: 2003 (1)](https://blog.scalehealth.com/tag/iso-13485-2003) - [ISO90003:2004 (1)](https://blog.scalehealth.com/tag/iso900032004) - [Intellectual Property (1)](https://blog.scalehealth.com/tag/intellectual-property) - [International Electrotechnical Commission (1)](https://blog.scalehealth.com/tag/international-electrotechnical-commission) - [International Organization for Standardization (1)](https://blog.scalehealth.com/tag/international-organization-for-standardization) - [Jira Server (1)](https://blog.scalehealth.com/tag/jira-server) - [Key Terms (1)](https://blog.scalehealth.com/tag/key-terms) - [Labeling (1)](https://blog.scalehealth.com/tag/labeling) - [Liability (1)](https://blog.scalehealth.com/tag/liability) - [MDSAP (1)](https://blog.scalehealth.com/tag/mdsap) - [METRC (1)](https://blog.scalehealth.com/tag/metrc) - [MHLW/PMDA (1)](https://blog.scalehealth.com/tag/mhlw-pmda) - [Management Controls (1)](https://blog.scalehealth.com/tag/management-controls) - [Masks (1)](https://blog.scalehealth.com/tag/masks) - [Medical Device Single Audit Program (1)](https://blog.scalehealth.com/tag/medical-device-single-audit-program) - [Medical Marijuana (1)](https://blog.scalehealth.com/tag/medical-marijuana) - [Ministry of Health, Labour and Welfare (1)](https://blog.scalehealth.com/tag/ministry-of-health-labour-and-welfare) - [Myths (1)](https://blog.scalehealth.com/tag/myths) - [New Approach Directives (1)](https://blog.scalehealth.com/tag/new-approach-directives) - [New Drug Application (1)](https://blog.scalehealth.com/tag/new-drug-application) - [Nonconformity (1)](https://blog.scalehealth.com/tag/nonconformity) - [PCCP (1)](https://blog.scalehealth.com/tag/pccp) - [PRD (1)](https://blog.scalehealth.com/tag/prd) - [Pandemic (1)](https://blog.scalehealth.com/tag/pandemic) - [Part 11 (1)](https://blog.scalehealth.com/tag/part-11) - [Part 820.30 (1)](https://blog.scalehealth.com/tag/part-820-30) - [Performance Tests (1)](https://blog.scalehealth.com/tag/performance-tests) - [Preliminary Screening (1)](https://blog.scalehealth.com/tag/preliminary-screening) - [Project Deliverables (1)](https://blog.scalehealth.com/tag/project-deliverables) - [Project Timeline (1)](https://blog.scalehealth.com/tag/project-timeline) - [QA/RA (1)](https://blog.scalehealth.com/tag/qa-ra) - [QMSR (1)](https://blog.scalehealth.com/tag/qmsr) - [Regulatory Options (1)](https://blog.scalehealth.com/tag/regulatory-options) - [SRS (1)](https://blog.scalehealth.com/tag/srs) - [SaMD Risk Classification (1)](https://blog.scalehealth.com/tag/samd-risk-classification) - [SaMD for QMS (1)](https://blog.scalehealth.com/tag/samd-for-qms) - [SiMD (1)](https://blog.scalehealth.com/tag/simd) - [Software Architecture (1)](https://blog.scalehealth.com/tag/software-architecture) - [Sprints (1)](https://blog.scalehealth.com/tag/sprints) - [Substantial Equivalence (1)](https://blog.scalehealth.com/tag/substantial-equivalence) - [TGA (1)](https://blog.scalehealth.com/tag/tga) - [TSC (1)](https://blog.scalehealth.com/tag/tsc) - [Trust Services Criteria (1)](https://blog.scalehealth.com/tag/trust-services-criteria) - [Valid Clinical Association (1)](https://blog.scalehealth.com/tag/valid-clinical-association) - [Validation Testing (1)](https://blog.scalehealth.com/tag/validation-testing) - [Waterfall Method (1)](https://blog.scalehealth.com/tag/waterfall-method) - [Webinar (1)](https://blog.scalehealth.com/tag/webinar) - [Workflow Transitions (1)](https://blog.scalehealth.com/tag/workflow-transitions) - [abbreviated 510(k) (1)](https://blog.scalehealth.com/tag/abbreviated-510k) - [administrative evaluation (1)](https://blog.scalehealth.com/tag/administrative-evaluation) - [medical device quality management system (1)](https://blog.scalehealth.com/tag/medical-device-quality-management-system) - [paperless quality processes (1)](https://blog.scalehealth.com/tag/paperless-quality-processes) - [qms Samd (1)](https://blog.scalehealth.com/tag/qms-samd) - [qms cloud (1)](https://blog.scalehealth.com/tag/qms-cloud) - [refuse-to-accept (1)](https://blog.scalehealth.com/tag/refuse-to-accept) - [rta letter (1)](https://blog.scalehealth.com/tag/rta-letter) - [special 510(k) (1)](https://blog.scalehealth.com/tag/special-510k) - [traditional 510(k) (1)](https://blog.scalehealth.com/tag/traditional-510k) See all ### Subscribe Here - ![sierra-labs](https://blog.scalehealth.com/hubfs/Sierralabs_January2019%20Theme/Images/sierra-labs-logo.png) - © 2022 Sierra Labs, Inc. - Contact Us - [hello@sierralabs.com](mailto:hello@sierralabs.com) - 3415 S. Sepulveda Blvd. Suite 1000 Los Angeles, CA 90034 - (310) 437-8010 - Products - Company - [About Us](https://www.sierralabs.com/about)